SEC Form 4 · accession 0001104659-18-019665
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adrian Rawcliffe
Officer — Chief Financial Officer
Period of report
Mar 20, 2018
Accepted (ET)
Mar 22, 2018 · 9:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 20, 2018 | S | 600,000 | $1.71 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Ordinary Shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents six Ordinary Shares. The Ordinary Shares were obtained from the partial exercise of an option that was granted on March 16, 2015.
- F2The sale price of $1.71 per Ordinary Share was derived from the sale price of $10.27 per ADS on March 20, 2018 divided by six.